Reviva Pharmaceuticals Holdings Inc. (RVPH)
Official siteHEALTHCARE • BIOTECHNOLOGY • PINK
Market Cap: $4.63M
Last updated: Nov 16, 2026 at 4:00 PM ET
Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock Chart
Reviva Pharmaceuticals Holdings (RVPH) closed at $0.35 on Nov 16, 2026, 97.7% below its 52-week high of $15.40. Its price fell 96.8% over the past 12 months. The month-end price fell 99.8% since Oct 2018, a compound annual decline of 54.6%.
Price Chart
From Oct 2018 to Oct 2026, its highest month-end close was $219.20 in Nov 2020 and its lowest $0.35 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart RVPH with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for RVPH.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 23.8%, and over 6 months it fell 14.5%. The month-end price fell 99.6% over the 3 years through Oct 2026, a compound annual decline of 84.5%.
| Period | Change |
|---|---|
| 1 month | -25.5% |
| 3 months | -23.8% |
| 6 months | -14.5% |
| 12 months | -96.8% |
| 12 months, with dividends | -96.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -99.6% | -84.5% |
| 5 years | -99.5% | -65.3% |
| Since Oct 2018 | -99.8% | -54.6% |
Price by Year
Its best calendar year was 2022, when the price rose 47.1%, and its weakest was 2025, when it fell 84.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $0.35 | -93.7% |
| 2025 | $5.58 | -84.6% |
| 2024 | $36.20 | -64.9% |
| 2023 | $103.00 | +21.2% |
| 2022 | $85.00 | +47.1% |
| 2021 | $57.80 | -67.0% |
| 2020 | $174.90 | -16.4% |
Trading Range
The price is 23.1% below its 50-day average of $0.46 and 70.3% below its 200-day average of $1.18.
| Measure | Value | Price vs |
|---|---|---|
| Close (Nov 16, 2026) | $0.35 | |
| 52-week high | $15.40 | -97.7% |
| 52-week low | $0.26 | +33.7% |
| 50-day average | $0.46 | -23.1% |
| 200-day average | $1.18 | -70.3% |
Price Risk
Over 3 years, its largest fall from a peak was 99.7%.
| Measure | Value |
|---|---|
| 1-year beta | 1.41 |
| Largest fall, 1 year | -97.7% |
| Largest fall, 3 years | -99.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About RVPH
What is RVPH's 1-year price change?
Reviva Pharmaceuticals Holdings's price fell 96.8% over the past 12 months. With dividends included, the 12-month total return was -96.8%.
What is RVPH's 5-year price change?
Reviva Pharmaceuticals Holdings's month-end price fell 99.5% over the 5 years through Oct 2026, a compound annual decline of 65.3%. These figures leave out dividends.
What is RVPH's 52-week high and low?
Reviva Pharmaceuticals Holdings's 52-week high is $15.40 and its 52-week low is $0.26. Its close of $0.35 on Nov 16, 2026 is 97.7% below the high.
What is RVPH's beta?
Reviva Pharmaceuticals Holdings's 1-year beta against the S&P 500 is 1.41, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 97.7%.
Is the RVPH chart free?
Yes. Advanced Charting for RVPH is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
RVPH pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors